INVIVYD INC. - COMMON

Invivyd to Participate in Upcoming Investor Conferences

31 10 2023 16:01:00 提供 Nasdaq GlobeNewswire

Invivyd Announces Dosing of First Participant in CANOPY Phase 3 Pivotal Clinical Trial Investigating VYD222 for the Prevention of Symptomatic COVID-19 

11 9 2023 07:00:00 提供 Nasdaq GlobeNewswire

Invivyd to Participate in Upcoming Investor Conferences

06 9 2023 07:00:00 提供 Nasdaq GlobeNewswire

Invivyd Reports Second Quarter 2023 Financial Results and Business Highlights

10 8 2023 16:01:00 提供 Nasdaq GlobeNewswire

Invivyd to Host Conference Call Discussing Second Quarter 2023 Financial Results and Business Highlights

03 8 2023 16:01:00 提供 Nasdaq GlobeNewswire

Invivyd Announces Appointment of Sara Cotter to Board Of Directors

27 7 2023 16:01:00 提供 Nasdaq GlobeNewswire

Invivyd Announces Additional Positive Initial Data from Ongoing Phase 1 Clinical Trial of VYD222, a Monoclonal Antibody Candidate in Development for the Prevention of Symptomatic COVID-19 in Immunocompromised People

17 7 2023 07:00:00 提供 Nasdaq GlobeNewswire

Invivyd Announces General Alignment with FDA on Pathway to Potential EUA for VYD222 and Anticipated Follow-On Monoclonal Antibody Candidates Designed to Prevent COVID-19

26 6 2023 07:00:00 提供 Nasdaq GlobeNewswire

Invivyd Announces Positive Initial Data from Ongoing Phase 1 Clinical Trial of VYD222, a Monoclonal Antibody Candidate in Development for the Prevention of Symptomatic COVID-19 in Immunocompromised People

22 6 2023 07:00:00 提供 Nasdaq GlobeNewswire

Invivyd to Participate at the Jefferies Healthcare Conference

01 6 2023 07:00:00 提供 Nasdaq GlobeNewswire

Invivyd Reports First Quarter 2023 Financial Results and Business Highlights

11 5 2023 16:01:00 提供 Nasdaq GlobeNewswire

Invivyd to Host Conference Call Discussing First Quarter 2023 Financial Results and Business Highlights

04 5 2023 16:01:00 提供 Nasdaq GlobeNewswire

Invivyd to Participate at H.C. Wainwright’s BioConnect Investor Conference

25 4 2023 16:01:00 提供 Nasdaq GlobeNewswire

Invivyd Announces the FDA Has Cleared Its IND Application for VYD222, a Monoclonal Antibody Candidate for Prevention of COVID-19, and Provides Phase 1 VYD222 Clinical Trial Update

25 4 2023 07:00:00 提供 Nasdaq GlobeNewswire

Invivyd Appoints Robert Allen as Chief Scientific Officer and Stacy Price as Chief Technology and Manufacturing Officer

12 4 2023 07:00:00 提供 Nasdaq GlobeNewswire

Invivyd Doses First Participants in Phase 1 Trial of VYD222, a Novel Monoclonal Antibody Candidate for COVID-19

30 3 2023 16:01:00 提供 Nasdaq GlobeNewswire

Invivyd Reports Full Year 2022 Financial Results and Business Highlights

23 3 2023 16:01:00 提供 Nasdaq GlobeNewswire

Invivyd Publishes Model for Evaluating Biomarker Correlates of Protection for Monoclonal Antibodies Against Symptomatic COVID-19

22 3 2023 16:30:00 提供 Nasdaq GlobeNewswire

Invivyd to Host Conference Call Discussing Full Year 2022 Financial Results and Business Highlights

16 3 2023 07:00:00 提供 Nasdaq GlobeNewswire

Invivyd Optimizes Development Efficiency with Election of VYD222 for Near-Term Clinical Advancement to Address Urgent Unmet Need for COVID-19 Monoclonal Antibodies

06 3 2023 07:00:00 提供 Nasdaq GlobeNewswire